Evicenter
MarkdownMedical informationP&T meetings
Varegacestat (AL102)

Desmoid tumors

Also known as BMS-986115
Manufacturer
Immunome
Launch
Not announced
Last updated
177 sources

Product information and disease descriptionProduct descriptionProduct informationPharmacology

Pharmacodynamics

5 evidence topics · 3 sources

Exposure-response for safety in a pooled phase 1 to phase 3 population
Adverse event of interestIncidence, n (%)
Treatment-emergent serious adverse events“49 (31.2)”
Grade 2+ hypophosphatemia“47 (29.9)”
Grade 2+ fatigue“43 (27.4)”
Grade 2+ nausea/vomiting“31 (19.7)”
Grade 2+ diarrhea“59 (37.6)”
Ovarian toxicity“32 (50.0)”
Grade 2+ rash“58 (36.9)”
Grade 2+ ALT elevation“9 (5.7)”
Note“Safety analysis population count was (N = 157) for all endpoints except ovarian toxicity (N = 64).”